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Summary Abnormal Ca2+ cycling is important in various cardiac diseases. Evidence
has accumulated that dysregulation of Ca2+ release from the ryanodine receptor
(RyR2) plays a signiﬁcant role in cardiac dysfunction. Spontaneous Ca2+ release
through RyR2 during diastole decreases sarcoplasmic reticulum (SR) Ca2+ content,
and also induces delayed after depolarization (DAD) as a substrate for lethal arrhyth-
mia. Several disease-linked mutations in the RyR have been reported in patients
with catecholaminergic polymorphic ventricular tachycardia (CPVT) or arrythmo-
genic right ventricular cardiomyopathy type 2 (ARVC2). The unique distribution of
these mutation sites has produced the concept that the interaction among the puta-
tive regulatory domains within the RyR may play a key role in regulating the channel
opening, and that there seems to be a common abnormality in the channel disorder
between heart failure and CPVT/ARVC2. We review here the considerable body of
evidence regarding defective channel gating of RyR2 in the pathogenesis of heart
failure and lethal arrhythmia.
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Heart failure (HF) is a complex disorder charac-
terized by contractile dysfunction and activation of
neurohumoral factors [1]. Among a variety of fac-
tors, abnormal intracellular Ca2+ handling by the
sarcoplasmic reticulum (SR) plays a key role in the
pathogenesis of HF [2,3]. In particular, abnormal
SR Ca2+ release has been reported to play a criti-
cal role in abnormal Ca2+ handling in HF [2,3]. This
review focuses on the underlying mechanism of the
disease-linked channel disorder of the ryanodine
receptor (RyR).
Structure of RyR2 as a scaffolding
protein
The RyR exists as a scaffolding protein bound with
many accessory proteins, producing a huge macro-
molecular complex [4] (Fig. 1). About 90% of the
RyR polypeptide chain forms a bulky cytoplasmic
domain that modulates the channel function. The
remaining 10% of the RyR sequence (C-terminal
region) forms transmembrane and channel pore
regions. The RyR is a huge tetrameric protein, and
each monomer is constituted of ∼5000 amino acids
and has a molecular weight of 565 kDa. There are
three RyR isoforms in mammals. RyR1 is predomi-
nant in skeletal muscle [5] and RyR2 is predominant
in cardiac muscle [6]. RyR3 was ﬁrst cloned from
rabbit brain [7]. The amino acid sequences of these
three RyR isoforms reveal a high degree of sequence
homology (∼70%). Many regulatory proteins (i.e.
calmodulin (CaM), FKBP12.6 (calstabin2), protein
kinase A (PKA), protein phosphatase 1 (PP1), and
protein phosphatase 2A (PP2A)) bind to the RyR2,
forming a huge macromolecular complex [4]. Both
junctin and triadin, which anchor calsequestrin
bind to the luminal site of the RyR2 [4].
Role of various accessory proteins of
RyR2 in channel gatingFKBP12.6
FKBP12.6 is one of the important accessory pro-
teins of RyR2. FKBP12.6 binds tightly to RyR2
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nd stabilizes the channel [8]. The stoichiome-
ry of FKBP12.6 binding to RyR2 is approximately
our FKBP molecules per RyR tetramer (or one
KBP12.6 per RyR subunit) [8]. Marx et al. [9]
emonstrated that chronic and excess activation
f beta-adrenergic receptor induces PKA-mediated
yperphosphorylation of RyR2 at serine 2808, which
n turn dissociates FKBP12.6 from RyR2, thereby
ausing Ca2+ leak. This diastolic Ca2+ leak not only
epresses the SR Ca2+ load, but also serves as a sub-
trate for DAD, leading to lethal arrhythmia which
an trigger cardiac arrhythmia and lead to sud-
en death. In pacing-induced canine HF model,
e found (1) that spontaneous SR Ca2+ leak was
ediated through the conformational change of
yR2, and (2) that the stoichiometry of FKBP12.6
o RyR2 was signiﬁcantly decreased in associa-
ion with PKA-hyperphosphorylation of RyR2 [10].
ong-term hyperphosphorylation of RyR2 in failing
earts seems to be maintained through a reduc-
ion in RyR2-coupled PP1, PP2A [9], and PDE4D3
11].
However, several researchers have challenged
he role of FKBP12.6 as a channel stabilizer in
arious experimental conditions. Phosphorylation
t serine2808 did not dissociate FKBP12.6 from
yR2 [12], and the constitutive phosphorylation of
erine2808 by mutations (S2808D) failed to dis-
upt the FKBP12.6—RyR2 interaction [13]. Chen and
is co-workers emphasized the signiﬁcant role of
KA phosphorylation of another site (Ser-2030) on
yper-sensitized channel to activation by luminal
a2+ (SOICR) in disease-linked Ry2 channel disor-
er [14—16]. Further investigation is still needed
o clarify the role of phosphorylation on RyR2
unction.
almodulin
almodulin is a 17-kDa ubiquitous Ca2+-binding pro-
ein that regulates channel opening by its direct
inding to the RyR. CaM is composed of ∼150
mino acid residues arranged in two globular lobes.
2+he Ca binding EF-hand motifs are arranged in
airs: one pair per lobe. The Ca2+ free and Ca2+
ound forms of CaM are termed apoCaM and CaCaM,
espectively. In RyR1, CaM enhances the chan-
el activity at low [Ca2+], whereas CaM inhibits
Role of ryanodine receptor 3
Figure 1 RyR2 macromolecular complex. Cardiac RyR (RyR2) and satellite proteins are indicated. Calmodulin (CaM),
FKBP12.6 (calstabin2), protein kinase A (PKA), phosphatase 1 (PP1), and phosphatase 2A (PP2A) bind to the cytoplasmic
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Cegion of the RyR. Both junctin and triadin, which anchor c
ind to the luminal side of RyR2.
t at high [Ca2+] [17]. RyR2, on the other hand,
oes not show activation by apoCaM but is inhib-
ted by CaCaM at all [Ca2+] [18,19]. In both RyR1
nd RyR2 isoforms, one CaM binds to one sub-
nit of RyR [20,21]. The CaM binding in RyR1 has
een shown to be within the residues 3614—3643
22], which are highly homologous to the residues
583—3603 of RyR2. The fact that mutation of sev-
ral critical residues in this region abolished CaM
inding to RyR2 [19] supports the notion that RyR1
nd RyR2 have at least one common CaM binding
omain (CaMBD) in the corresponding 3614—3643
nd 3583—3603 regions, respectively. The criti-
al role of the CaM binding to RyR2 on cardiac
evelopment has been recently shown using the
I mice model, in which the binding site of CaM
s mutated (W3587A/L3591D/F3603A) so as not to
ind with RyR2 [22]. Interestingly, the KI mice
howed a phenotype of hypertrophic cardiomyopa-
hy with severely impaired systolic function, and
igher mortality [22]. Of note, HDAC/MEF2 sig-
aling was found to be enhanced in KI hearts at
ay 1, suggesting that an altered SR Ca2+ release,
ia defective regulation of CaM on RyR2, increases
aMK II activity and HDAC phosphorylation, thereby
C
b
a
mquestrin to RyR2 depending on the SR Ca2+ concentration,
esulting in abnormal hypertrophic response as
een in the dilated phase of human hypertrophic
ardiomyopathy. Collectively, CaM binding to RyR2
eems to be essential for the physiologic struc-
ure and function of the heart. CaM is also
substrate for CaM kinase II-induced phospho-
ylation of RyR2, activating RyR opening and
nhancing diastolic SR Ca2+ release [23]. CaMK
I-C overexpression showed dilated cardiomy-
pathy with an increased diastolic Ca spark
requency and fractional SR Ca2+ release, despite
reduced SR Ca2+ content [24]. The CaMK II-
ependent RyR2 phosphorylation seems to be
eneﬁcial for efﬁcient activation of SR Ca2+ release
n each heart beat, but the over-activation or
ong-term activation of RyR2 by CaMK II phospho-
ylation may disturb cardiac function, resulting
n HF.
alsequestrinalsequestrin (CASQ) is a major intra-SR Ca2+-
inding protein. CASQ is highly acidic with 119 Glu
nd Asp residues (net 64 negative charge) and each
olecule binds ∼20 Ca ions with low afﬁnity [25].
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CASQ forms a complex with the RyR2, triadin, and
junction. Both skeletal and cardiac CASQ can bind
up to 800 nM of Ca2+ per mg of protein (40 ions per
molecule) with a Kd of about 1mM [25]. Upon Ca2+
binding, CASQ undergoes major conformational
changes, which enables high capacity Ca2+ bind-
ing by CASQ [26]. In addition to its Ca2+ buffering
action, calsequestrin has been shown to regulate
RyR2 function as a luminal Ca2+ sensor of RyR2 (via
protein—protein interactions involving triadin and
junctin) [27]. Namely, it is suggested that the open
probability of RyR2 is inhibited by CASQ at low intra-
SR [Ca2+], but that this inhibition is relieved at high
intra-SR [Ca2+], contributing to luminal [Ca2+] sens-
ing of RyR2 [27]. CASQ2 overexpression in mouse
hearts revealed increases in SR Ca2+ capacity, but
decreases in Ca2+-induced SR Ca2+ release, lead-
ing to depressed contractility [28]. Excessive Ca2+
buffering by high levels of CASQ2 may inhibit the
channel activity of RyR2. On the other hand, sev-
eral mutations in CASQ2 have been found to be
linked with CPVT [29—32]. Recently, a mouse model
in which CASQ2 is lacking [33] or mutated [34], has
been engineered. Interestingly, these mice showed
almost normal cardiac function, but developed
polymorphic ventricular tachycardia on infusion
of catecholamines, in association with signiﬁcant
compensatory change of CASQ-linked proteins: i.e.
increased expression of the luminal Ca2+-binding
protein calreticulin, reductions in triadin, and junc-
tion levels. Importantly, CASQ2-deﬁcient myocytes
showed an increased probability of Ca2+ release
with rather low intra-SR [Ca2+]. Bilayer studies
have also demonstrated that the removal of Casq2
increased RyR2 open probability at ﬁxed luminal
[Ca2+] [35]. Defective protein—protein interaction
between RyR2, CASQ2, triadin, and junctin may
be caused by a mutation of CASQ2, resulting in
a sensitized channel by luminal Ca2+ activation
upon adrenergic stimulation, rendering the channel
leaky.
Defective inter-domain interaction
within RyR2 in diseased hearts
More than 70 RyR2 miss-sense mutations have
been found to be linked with two inherited forms
of sudden cardiac death: i.e. catecholaminergic
polymorphic ventricular tachycardia (CPVT) and
arrhythmogenic right ventricular cardiomyopathy
type 2 (ARVD/C2) [3]. All these mutations are
not randomly distributed, but cluster into speciﬁc
regions that correspond to three malignant hyper-
thermia (MH)/central core disease (CCD) mutable
domain of RyR1: N-terminal domain (1—600),
c
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entral domain (2000—2500) and channel form-
ng, C-terminal domain). Mutations at different
ositions in ither domain seem to result in hyperac-
ivation of the Ca2+ channel and hypersensitization
o agonists. From these observations, Ikemoto and
amamoto [36] proposed an inter-domain interac-
ion concept that the two domains (N-terminal:
—600 and central domain: 2000—2500) interact
ith each other to act as a regulatory switch
or channel-gating activity, with a tight zipping of
he interacting domains serving to stabilize the
hannel. A mutation in either domain weakens
he inter-domain interaction, thus increasing the
endency towards unzipping, which causes acti-
ation and leakiness of the Ca2+ channel. We
emonstrated that the domain unzipping of the
nteracting domains have already taken place in
ailing hearts, concurrently with an abnormal Ca2+
eak, suggesting that defective inter-domain inter-
ction between the regulatory domains may be
key mechanism for the development of the
arious problems with RyR2 in the failing heart
37]. The previous observation by single particle
nalysis that the N-terminal and central mutation
egions are closely neighboring in the three-
imensional structure (domains 5 and 6 in the clamp
egion, respectively) [38] strongly supports the
nter-domain interaction concept. More recently,
eng et al. [39] reported that Ser-2808 is three-
imensionally located at the boundary between the
omain 5 and 6 at the clamp region, suggesting
hat PKA phosphorylation at Ser-2808 may possi-
ly interrupt the inter-domain interaction between
-terminal and central domains, causing domain
nzipping. RyR2 I-domain (3722—4610) was also
ound to communicate the cytoplasmic domain with
he transmembrane domain, thereby modulating
yR sensitivity to caffeine activation [40]. Inter-
stingly, I-domain (human CPVT-type) mutations
ccurring in domains III (N4104K) and IV (R4497C),
nd a distinct mutation occurring in domain II
S2246L), promoted equivalent augmentation in
hannel instability [40]. These ﬁndings suggest
hat defective inter-domain interaction may be
key pathogenic mechanism of HF and lethal
rrhythmia.
Recently, three types of knock-in mice with
he human CPVT/ARVC-associated RyR2 mutation:
4496C [41], R176Q [42], and R2474S [43] have
een generated, and in these mice, ventricu-
ar tachycardia was induced after injection of
affeine plus epinephrine or exercise. These ﬁnd-
ngs clearly indicate that single point mutation
ausatively induces lethal arrhythmia, although the
nderlying mechanism of lethal arrhythmia is still
nclear.
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orrection of defective inter-domain
nteraction as a new treatment for
iseased hearts
oth beta-blockers and angiotensin II receptor
lockade (ARB) were found to suppress the hyper-
drenergic state, thereby reversing PKA-mediated
yperphosphorylation of the RyR2, restoring the
KBP12.6-mediated stabilization and inhibiting the
a2+ leak [44—46]. Furthermore, we previously
eported that a 1,4-benzothiazepine derivative
201 (JTV519), improved contractility and pre-
ented the development of HF, probably by
ealing Ca2+ leak from RyR2 [47]. JTV519 was
ound to restore the zipped state of interactions
etween domains within RyR2, which prevented
a2+ leak from occurring in failing hearts [37]. We
ecently identiﬁed the K201-binding site as domain
114—2149 of the ryanodine receptor (RyR2), and
he binding of K201 to this domain corrects the
efective inter-domain interaction between N-
erminal (1—600) and central regions (2000—2500)
f RyR2 in pacing-induced failing hearts [48].
sing FKBP12.6 +/−mice, Wehrens et al. [49] also
emonstrated that JTV519 increased the afﬁnity of
KBP12.6 for the RyR2, which stabilized the closed
tate of the RyR2 and prevented the Ca2+ leak that
riggers arrhythmias. Taken together, the stabiliza-
ion of the RyR2 represents a new molecular target
or the treatment or prevention of lethal arrhyth-
ia and HF as well.
onclusions and perspectives
yR2, as a scaffolding Ca2+ regulatory protein, plays
crucial role in the pathogenesis of HF and car-
iac arrhythmia. Several accessory proteins; i.e.
KBP12.6, calmodulin, calsequestrin, PP1, PP2A,
tc., act as an important modulator for maintain-
ng normal Ca2+ cycling. Defective regulation of
hannel gating by these key proteins may render
he channel leaky. Defective inter-domain interac-
ion within the RyR2 also induces the de-stabilized
hannel gating, as a common key pathogenic mech-
nism of HF and lethal arrhythmia. Correction of
he defective domain—domain interaction would
e a possible new strategy against these diseased
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